Name
GS1-01 - KEYNOTE-522 Study of Neoadjuvant Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy, Followed by Adjuvant Pembrolizumab vs Placebo for Early-Stage TNBC: Event-Free Survival Sensitivity and Subgroup Analyses
Date & Time
Tuesday, December 7, 2021
Speakers
Virtual Session Link